Clinigen Group’s (CLIN) Buy Rating Reiterated at Liberum Capital

Liberum Capital reaffirmed their buy rating on shares of Clinigen Group (LON:CLIN) in a report issued on Tuesday, ThisIsMoney.Co.Uk reports.

A number of other research firms also recently issued reports on CLIN. Royal Bank of Canada reissued a top pick rating and issued a GBX 1,500 ($19.73) price target (down from GBX 1,600 ($21.05)) on shares of Clinigen Group in a research note on Friday, March 20th. Peel Hunt reissued a buy rating on shares of Clinigen Group in a research note on Thursday, March 5th.

Shares of LON:CLIN opened at GBX 498.20 ($6.55) on Tuesday. The company has a market cap of $635.55 million and a price-to-earnings ratio of 47.90. The company has a 50-day moving average price of GBX 724.83 and a 200-day moving average price of GBX 847.21. The company has a current ratio of 1.12, a quick ratio of 0.86 and a debt-to-equity ratio of 82.15. Clinigen Group has a 12 month low of GBX 600.50 ($7.90) and a 12 month high of GBX 1,069 ($14.06).

Clinigen Group (LON:CLIN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported GBX 30.80 ($0.41) EPS for the quarter, missing the consensus estimate of GBX 31 ($0.41) by GBX (0.20) ($0.00). As a group, research analysts forecast that Clinigen Group will post 2573.0001139 EPS for the current fiscal year.

The firm also recently disclosed a dividend, which will be paid on Friday, April 17th. Shareholders of record on Thursday, March 19th will be issued a GBX 2.15 ($0.03) dividend. This represents a yield of 0.29%. The ex-dividend date is Thursday, March 19th. Clinigen Group’s dividend payout ratio (DPR) is presently 0.67%.

In other Clinigen Group news, insider Shaun Edward Chilton acquired 10,000 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were acquired at an average price of GBX 416 ($5.47) per share, for a total transaction of £41,600 ($54,722.44).

Clinigen Group Company Profile

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

Featured Article: FAANG Stocks

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with's FREE daily email newsletter.